People
The People
Grade C+. Senores is a founder-led business with genuine promoter skin-in-the-game — but a pending criminal complaint against a sitting director, an MD on the Audit Committee, a web of related-party relationships via Remus Pharmaceuticals, and post-IPO warrant dilution to promoters create structural governance concerns that go beyond normal Indian small-cap friction.
The People Running This Company
Jitendra Babulal Sanghvi (Non-Executive Director, DIN 00271995) remains on the Senores board despite being named in a pending criminal complaint filed by the Drugs Inspector (CDSC) alleging Ratnatris Pharmaceuticals intentionally manufactured substandard Metformin tablets. He is also listed as a director of Remus Pharmaceuticals. The case is unresolved as of this report. The board has not disclosed any remediation or recusal.
Swapnil Shah is the real decision-maker. He sets strategy, leads earnings calls, drives acquisitions (Havix, RPPL, Apnar Pharma, Zoraya), and holds the largest individual equity stake. His background at a Delaware pharma company before founding Senores in 2017 gives him genuine US-market credibility. The documented governance concerns include: he is simultaneously Chairman of a listed peer (Remus Pharmaceuticals), sits on his own Audit Committee, and used a roundabout warrant structure post-IPO to fund a subsidiary with cash from promoter entities.
Sanjay Majmudar plays an active, credibility-adding role on calls — he corrects numbers in real time, offers strategic context, and handles the harder analyst questions. His presence on AIA Engineering (a respectable industrial Gujarati business) adds credibility.
What They Get Paid
Pay looks restrained relative to a ₹4,367 Cr market cap. The MD's ₹3 Cr salary is 0.07% of market cap — well below Indian pharma peer norms where founders of similar-sized businesses earn ₹8–12 Cr. However, Dr. Vijay Malik's detailed IPO prospectus analysis notes promoter remuneration escalated sharply in the IPO year, and that in FY2024 aggregate employee compensation actually declined while founder pay rose. The real compensation event was the IPO OFS — promoters and early investors reportedly earned 900–1,500% returns on shares sold during the December 2024 listing.
Independent directors receive only sitting fees (₹4–40 lakh range). No commission, no stock options for independent directors.
Are They Aligned?
Promoter Ownership
Promoter holding has been remarkably stable at 45.8% across six quarters post-IPO — no selling by promoters in the open market. The DII holding declined from 11.8% → 9.6%, suggesting some institutional profit-taking. Public holding rose from 38.2% to 40.9%.
Post-warrant conversion (if fully exercised): Promoters would hold 2,22,70,357 shares = 47.16% — a 1.34 percentage point increase via preferential route.
Warrant Allotment: Alignment or Self-Dealing?
On March 28, 2026, the board allotted 11,70,000 convertible equity warrants at ₹812/warrant (total value ₹95 Cr) to five promoter/group entities. Only 25% (₹23.75 Cr) was paid upfront; the remaining ₹71.25 Cr is due on conversion within 18 months.
What this means: (1) Promoters gain option value — if the stock is above ₹812 at conversion, they profit; if below, they walk away. (2) The stated purpose is to provide a working capital loan to Apnar Pharma Private Limited — meaning the company is routing capital through a preferential issue to promoters who then lend it to a subsidiary. This is a circuitous structure when a rights issue or public NCD would serve the same purpose more equitably. (3) Viraj Ashokkumar Barot (presumably a family member of promoter Ashok Barot) enters the promoter group for the first time via warrants — 49,500 warrants from zero shares.
The ₹95 Cr warrant issue to promoters is SEBI-compliant (EGM approved Jan 31, 2026) but the structure is dilutive to public shareholders and roundabout. Promoters pay only 25% upfront, retain the right to not convert if stock falls below ₹812, and the stated use of funds (working capital for Apnar Pharma) could have been achieved through a subsidiary-level loan or rights offering.
Pledge History
The pledge activity in Dec 2025–Feb 2026 was a rotation: Renosen released its 400K pledge with Bajaj Finance, while Espee Therapeutics LLP created a new pledge on 400K shares to a different lender. The net effect is zero change in total encumbrance. Swapnil Shah's direct shares carry no pledge. However, pledge activity on promoter-group entities does suggest short-term liquidity needs at the promoter-group level even as the listed entity has strong earnings growth.
Related-Party Web: Remus Pharmaceuticals
Swapnil Shah (MD of Senores) is simultaneously Chairman and Whole-Time Director of Remus Pharmaceuticals Limited (a separately listed pharma company). Arpit Shah (Non-Exec Director of Senores) is the Managing Director of Remus Pharmaceuticals. Both serve on Senores' board while running a listed peer. Any commercial transactions between Senores and Remus require rigorous scrutiny — though the company states all RPTs are arm's-length and Audit Committee-approved, the optics of both chairman and MD at the related entity sitting on Senores' board creates structural conflict.
Zoraya JV risk: In November 2025, Senores acquired 51% of Zoraya Pharmaceuticals LLC (Delaware) — a new entity targeting US government supply (controlled substances / BAA-compliant). The 49% minority partner's identity is not publicly disclosed in any BSE/NSE filing. A US government-supply venture with an unnamed partner is a meaningful due-diligence gap.
Skin-in-the-Game Score:
Skin-in-Game Score (out of 10)
Board Quality
Board quality assessment:
- Composition: 4 independent directors = 33% of board — exactly the SEBI LODR minimum. No buffer above the regulatory floor.
- Audit Committee structural weakness: The MD (Swapnil Shah) is a member of the Audit Committee, alongside three independent directors. This is LODR-compliant but undermines the committee's role as a check on management. The Audit Chair (Kalpit Gandhi, CFO of Vadilal Industries) is qualified and diligent (10/10 attendance), but the MD's presence limits the committee's ability to challenge management on financial reporting.
- Director under criminal complaint: Jitendra Sanghvi (Non-Exec) is named in a pending CDSC criminal complaint over substandard drug manufacturing at RPPL. The board has not disclosed recusal or any governance response to this situation.
- Attendance outliers: Hemanshu Pandya (2/15, 13%) and Manjula Shroff (4/15, 27%) have attendance too low to provide meaningful oversight. Manjula Shroff also missed the last AGM.
- Committee quality: The four independent directors chair all four major committees (Audit, NRC, SRC, Risk). This is structurally sound. However, the NRC (which sets pay) includes non-independent Sanjay Majmudar as a member alongside two IDs — he effectively has a vote on the MD's compensation.
- No red flag on compliance: FY2026 CG report shows all LODR Reg 17-26 affirmations as "Yes." No penalty or fine from SEBI/exchanges in any period under review.
The Verdict
Skin-in-Game (/ 10)
Board Independence (%)
Strongest positives:
- Founder-operator with genuine equity: Swapnil Shah's direct holding (~7.7% of shares = ~₹337 Cr at market) is a real stake that incentivizes long-term performance.
- Clean compliance record at the critical Atlanta USFDA plant — no 483 observations, four clean audits.
- Pay is modest by industry norms; no ESOP dilution or outsized cash extraction via salary.
- All LODR affirmations clean for FY2026 with zero exchange penalties.
- Audit Committee chairman (Kalpit Gandhi) is financially qualified and attended 10/10 committee meetings.
Real concerns:
- Jitendra Sanghvi sitting problem: A director with a pending criminal complaint for intentional substandard drug manufacturing has not been asked to step down or recuse. If conviction occurs, the reputational and regulatory damage is severe. This is the single biggest governance risk — and it is economically material because RPPL supplies 30%+ of revenue.
- MD on Audit Committee: A structural conflict that reduces the independence of the most important board committee. Any investor placing weight on earnings quality must discount this.
- Remus Pharmaceuticals entanglement: Swapnil Shah runs both Senores and Remus. Arpit Shah runs Remus and sits on Senores. Until related-party flows are transparently disclosed and independently verified, this creates an inherent conflict that requires ongoing monitoring.
- Promoter warrant structure: The ₹95 Cr warrant to promoters at ₹812/share to fund Apnar Pharma working capital is a non-arm's-length capital structure that effectively gives promoters cheap optionality on a subsidiary-investment cycle.
- Zoraya JV partner undisclosed: A 49% partner in a US government-supply entity is a material unknown.
What would change the grade:
- Upgrade trigger: Jitendra Sanghvi's criminal case resolved with acquittal AND he resigns from the board; MD removed from Audit Committee; Zoraya partner identity disclosed; NRC shifts to majority-independent composition. These changes would lift the grade to B–.
- Downgrade trigger: Criminal complaint results in conviction; RPPL suffers another license suspension materially impacting emerging market revenue; Remus-Senores RPT volumes revealed to be non-arm's-length; warrants partially exercised in a below-market conversion.